TABLE 4.

Neuropsychiatric events in subjects on tafeoquine or mefloquine (prophylactic phase)a

Adverse eventNo. (%) of subjects by AE severity and treatment group
MildModerateTotal
TafenoquineMefloquineTafenoquineMefloquineTafenoquineMefloquine
Vertigo22 (5)7 (4)01 (<1)22 (5)8 (5)
Somnolence12 (2)6 (4)0012 (2)6 (4)
Abnormal dreams7 (1)2 (1)007 (1)2 (1)
Dizziness5 (1)2 (1)005 (1)2 (1)
Insomnia4 (<1)3 (2)1 (<1)05 (1)3 (2)
Abnormal coordination2 (<1)1 (<1)002 (<1)1 (<1)
Anxiety2 (<1)0002 (<1)0
Agitation2 (<1)0002 (<1)0
Euphoria2 (<1)0002 (<1)0
Tremor2 (<1)0002 (<1)0
Depression001 (<1)1 (<1)1 (<1)1 (<1)
Paroniria1 (<1)0001 (<1)0
Amnesia1 (<1)0001 (<1)0
  • a In total, there were 492 tafenoquine subjects and 162 mefloquine subjects. There were no severe adverse events (AEs) of this type.